NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SYBX

Synlogic Inc

Jul 01 • 12:44PM ET

1.22

Dollar change -0.05
Percentage change -3.94	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP SRPT ALNY NTLA BLUE EDIT BEAM QURE ARCT SGMO

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	10.41	EPS (ttm)	0.12	Insider Own	36.95%	Shs Outstand	11.70M	Perf Week	2.26%
Market Cap	14.27M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.05%	Shs Float	7.37M	Perf Month	6.09%
Enterprise Value	-3.00M	PEG	-	EPS next Q	-	Inst Own	38.12%	Short Float	0.53%	Perf Quarter	-4.69%
Income	1.50M	P/S	-	EPS this Y	-	Inst Trans	-47.46%	Short Ratio	3.44	Perf Half Y	-12.23%
Sales	0.00M	P/B	1.09	EPS next Y	-	ROA	5.55%	Short Interest	0.04M	Perf YTD	-12.86%
Book/sh	1.12	P/C	0.83	EPS next 5Y	-	ROE	11.34%	52W High	1.88 -35.11%	Perf Year	-19.74%
Cash/sh	1.48	P/FCF	-	EPS past 3/5Y	51.14% 40.39%	ROIC	11.44%	52W Low	0.90 35.86%	Perf 3Y	-92.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-83.42% -67.55%	Gross Margin	-	Volatility	3.05% 3.64%	Perf 5Y	-96.34%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	101.19%	Oper. Margin	-	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.68	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	51.62	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.68	EPS Q/Q	100.98%	SMA20	-0.49%	Beta	0.55	Target Price	1.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	4.22%	Rel Volume	1.40	Prev Close	1.27
Employees	1	LT Debt/Eq	0.00	Earnings	-	SMA200	-8.15%	Avg Volume	11.34K	Price	1.22
IPO	Oct 01, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	94.44% -	Trades		Volume	8,290	Change	-3.94%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-21	Upgrade	Oppenheimer	Perform → Outperform	$7
Aug-21-19	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-19	Initiated	Jefferies	Buy	$18
Dec-13-18	Initiated	Chardan Capital Markets	Buy	$20
Mar-19-18	Initiated	H.C. Wainwright	Buy	$20
Jan-29-18	Initiated	Piper Jaffray	Overweight	$16

Mar-26-25 08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Nov-12-24 04:35PM	Synlogic Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Aug-09-24 09:33AM	Otsuka snaps up Jnana with its phenylketonuria drug for $800m (Clinical Trials Arena) -7.01%
Aug-08-24 07:00AM	Synlogic Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 11:42AM	Otsuka snaps up Jnana with its phenylketonuria drug for $800m (Pharmaceutical Technology)
03:29PM	Loading…
May-23-24 03:29PM	The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits (InvestorPlace)
May-14-24 01:54PM	SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Synlogic Reports First Quarter 2024 Financial Results (GlobeNewswire)
Mar-19-24 08:10AM	Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.32%
07:00AM	Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-20-24 12:15PM	Synlogic Adopts Limited Duration Stockholders Rights Plan (GlobeNewswire)
Feb-09-24 09:41AM	PayPal downgraded, United Airlines upgraded: Wall Street's top analyst calls (The Fly) -48.70%
08:42AM	Why Is Synlogic (SYBX) Stock Down 55% Today? (InvestorPlace)
05:47AM	Synlogic reaches end of line, laying off 90% of staff and ceasing operations after phase 3 fail (FierceBiotech.com)
Feb-08-24 04:15PM	Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update (GlobeNewswire)
12:00PM	Loading…
Feb-02-24 12:00PM	Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria (GlobeNewswire)
Jan-16-24 08:47AM	Sidoti Events, LLC's Virtual January Micro-Cap Conference (ACCESSWIRE) -6.08%
Jan-04-24 07:00AM	Synlogic Provides Corporate Update and Outlook for 2024 (GlobeNewswire)
Dec-27-23 07:00AM	Synlogic Announces Contract with the Air Force Research Lab (GlobeNewswire) -7.24%
Dec-07-23 07:00AM	Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023 (GlobeNewswire) +11.60%
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE) +17.78%
Nov-09-23 07:19AM	Synlogic Inc (SYBX) Reports Q3 2023 Financial Results with Extended Cash Runway and Clinical ... (GuruFocus.com) -15.02%
07:00AM	Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 07:00AM	Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration (GlobeNewswire)
Nov-02-23 10:00AM	Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-03-23 04:15PM	Synlogic Announces Closing of $21.0 Million Underwritten Public Offering (GlobeNewswire) -7.72% +10.65%
Sep-29-23 07:00AM	Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering (GlobeNewswire) -11.08%
Sep-28-23 11:15AM	Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism (GlobeNewswire) -24.49%
09:13AM	Why Is Synlogic (SYBX) Stock Down 6% Today? (InvestorPlace)
Sep-27-23 12:30PM	Synlogic Announces Reverse Stock Split (GlobeNewswire) -15.48%
07:00AM	Loading…
Sep-21-23 07:00AM	Synlogic to Participate in Chardans Genetic Medicines Conference (GlobeNewswire)
Sep-19-23 11:00AM	Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100 (GlobeNewswire) -21.79%
Aug-10-23 08:40AM	Synlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-11-23 07:00AM	Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria (GlobeNewswire) +5.49%
Jun-28-23 07:00AM	Synlogic Announces International Nonproprietary Name Selection for SYNB1934 (GlobeNewswire) -9.78%
Jun-27-23 07:00AM	Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum (GlobeNewswire) +15.68%
Jun-08-23 06:45AM	Synlogic Reminds Stockholders of 2023 Annual General Meeting Details (GlobeNewswire)
Jun-05-23 06:45AM	Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria (GlobeNewswire) -14.65%
May-24-23 06:35AM	Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference (GlobeNewswire)
May-23-23 06:50AM	Synlogic to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-23 08:21AM	Synlogic First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-11-23 12:38PM	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year (InvestorPlace)
08:05AM	Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
06:50AM	Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) -10.36%
06:50AM	Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria (GlobeNewswire)
May-04-23 10:00AM	Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-28-23 05:12PM	3 Megatrend Stocks to Buy for 10x Potential Returns (InvestorPlace)
Mar-29-23 07:55AM	Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
06:40AM	Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates (GlobeNewswire)
Mar-28-23 06:52AM	Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria (GlobeNewswire) +5.32%
Mar-20-23 06:55AM	Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting (GlobeNewswire) +7.81%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -10.37%
Mar-08-23 07:00AM	Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
06:57AM	Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting (GlobeNewswire)
Jan-24-23 06:57AM	Synlogic Announces Participation in Upcoming Investor and Industry Conferences (GlobeNewswire)
Jan-19-23 06:58AM	Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU) (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Jan-16-23 12:00PM	Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why (Zacks)
Jan-14-23 07:17AM	Even after rising 15% this past week, Synlogic (NASDAQ:SYBX) shareholders are still down 90% over the past five years (Simply Wall St.)
Jan-05-23 06:58AM	Synlogic Provides Corporate Update and Outlook for 2023 (GlobeNewswire) +11.33%
Jan-03-23 06:58AM	Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development (GlobeNewswire)
Dec-15-22 10:49AM	Synlogic's Experimental Drug Lowers Urinary Oxalate In Gastric Bypass Patients (Benzinga) +8.28%
06:59AM	Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study (GlobeNewswire)
Dec-04-22 09:27AM	Will Synlogic (NASDAQ:SYBX) Spend Its Cash Wisely? (Simply Wall St.)
Nov-30-22 04:15PM	Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update (GlobeNewswire) +15.38%
Nov-10-22 08:05AM	Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.88%
06:59AM	Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-18-22 11:15AM	Synlogic Touts Positive Data From Rare Inherited Disorder Trial, Pivotal Study To Start Next Year (Benzinga)
06:59AM	Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3 (GlobeNewswire)
Sep-06-22 07:00AM	Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease (GlobeNewswire)
Aug-23-22 07:00AM	Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU) (GlobeNewswire)
Aug-11-22 03:50PM	Ginkgo Bioworks partners with Synlogic on new gout drug (Yahoo Finance Video) +11.22%
08:15AM	Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks (PR Newswire)
06:58AM	Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-22 07:00AM	Synlogic Announces Second Quarter 2022 Conference Call and Webcast (GlobeNewswire) -7.58%
Jul-12-22 07:00AM	Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU) (GlobeNewswire)
Jun-29-22 07:00AM	Synlogic Announces Appointment of General Counsel and Corporate Secretary (GlobeNewswire)
Jun-28-22 07:00AM	Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference (GlobeNewswire) -6.19%
Jun-27-22 10:06AM	Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jun-21-22 07:00AM	Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference (GlobeNewswire) +9.62%
Jun-01-22 07:00AM	Synlogic Reminds Stockholders of 2022 Annual General Meeting Details (GlobeNewswire)
May-24-22 07:00AM	Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria (GlobeNewswire) -7.44%
May-12-22 10:51AM	Synlogic (NASDAQ:SYBX shareholders incur further losses as stock declines 28% this week, taking three-year losses to 85% (Simply Wall St.) -14.40%
08:35AM	Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-05-22 07:00AM	Synlogic Announces First Quarter 2022 Conference Call and Webcast (GlobeNewswire) -6.36%
Apr-28-22 07:00AM	Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium (GlobeNewswire)
Apr-26-22 07:00AM	Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference (GlobeNewswire)
Apr-01-22 07:00AM	Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting (GlobeNewswire)
Mar-17-22 08:25AM	Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-10-22 07:00AM	Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast (GlobeNewswire)
Mar-03-22 07:00AM	Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer (GlobeNewswire)
Feb-24-22 07:00AM	Synlogic To Present at Upcoming Investor and Industry Conferences (GlobeNewswire)
Feb-08-22 07:00AM	Synlogic To Present at Upcoming Investor and Industry Conferences (GlobeNewswire)
Jan-11-22 08:59AM	Will Synlogic (NASDAQ:SYBX) Spend Its Cash Wisely? (Simply Wall St.)

Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dooley Mary Beth	See Remarks below	Apr 02 '25	Sale	1.20	144	173	12,901	Apr 03 04:30 PM
Dooley Mary Beth	See Remarks below	Feb 03 '25	Sale	1.33	2,107	2,802	13,045	Feb 04 05:53 PM
Dooley Mary Beth	Head of Finance	Oct 29 '24	Sale	1.40	79	111	15,152	Oct 30 07:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SYBX

Synlogic Inc

Upgrade your FINVIZ experience